P. Mando, G. Guaygua Loayza, A. Borello, M.A. Lutteral, M.F. Illia, M.A. Nunell, L. Cermignani, I. Robledo Salas, F. S. E. Monteagudo, L. Gonzalez, M.B. Cieplinski, J. Mandrile, A. Mazzotta, M.C.A. Elaskar, M.A. Iriso, M.B. Montenegro, M. G. Ferreira, A. gallardo, M.D. Broilo, F.D. Waisberg
Adjuvant CDK4/6 inhibitors are standard of care for patients with intermediate- and high-risk HR+/HER2– early breast cancer. However, treatment-related toxicities and quality-of-life impairment may affect adherence. Dose adjustments are commonly used to improve tolerance, particularly in older patients, though real-world data are limited.